Table 1.
Baseline participants’ characteristics by aspirin treatment outcomes at four weeks
| All participants (N=39) |
Baseline values by aspirin desensitization outcomes* | |||||
|---|---|---|---|---|---|---|
| Improvement in symptoms (N=16) |
No change in symptoms (N=4) |
Worsening of symptoms (N=12) |
Desensitization not completed (N=7) |
P-value for comparison between four groups |
||
| Age, years (±SEM) | 41.7 (±1.7) | 42.3 (±2.8) | 43.5 (±2.5) | 42.2 (±3.3) | 48.3 (±4.7) | 0.8 |
| Women, N (%) | 26 (66.7) | 10 (62.5) | 3 (75.0) | 9 (75.0) | 4 (57.14) | 0.9 |
| Race, N (%) | 0.02 | |||||
| African-American | 20 (51.3) | 4 (25.0) | 1 (25.0) | 9 (75.0) | 6 (85.7) | |
| Latino | 12 (30.7) | 6 (37.5) | 2 (50.0) | 3 (25.0) | 1 (14.3) | |
| White, non-Latino | 7 (18.0) | 6 (37.5) | 1 (25.0) | 0 | 0 | |
| Asthma duration, years (IQR) | 9.0 (3–19) | 13.0 (5–19.5) | 5.0 (3–7.5) | 5.0 (3–23) | 7 (3–22) | 0.4 |
| Rhinitis duration, years (IQR) | 7.0 (4–13) | 8.5 (4.5–17) | 7.5 (4.5–10) | 10.0 (3–17) | 5.0 (2–12) | 0.6 |
| Nasal polyp duration, years (IQR) | 5.0 (2–7) | 5.5 (3–12.5) | 7.0 (4.5–8.5) | 3.5 (1–7) | 2.0 (1–5) | 0.2 |
|
Aspirin hypersensitivity duration years (IQR) |
5.0 (1–11) | 4.5 (2–18) | 3.0 (1–5.5) | 5.0 (1–10) | 6.0 (1–11) | 0.7 |
| History of ESS, N (%) | 33 (84.6) | 15 (94) | 4 (100) | 8 (67) | 6 (86) | 0.3 |
|
Time since last ESS before desensitization, months (IQR) |
32.0 (9–72) | 32.0 (6–72) | 78 (37–90) | 19.5 (9.5–66) | 36.0 (20–72) | 0.9 |
| Use of high-dose ICS, N (%) | 29 (74.4) | 11 (69) | 2 (50) | 10 (83.3) | 6 (86) | 0.5 |
| Use of omalizumab, % | 7 (18) | 3 (19) | 0 | 2 (17.0) | 2 (29.0) | 0.8 |
| Chronic use of oral prednisone, N (%) | 9 (23.1) | 3 (18.75) | 1 (25.0) | 1 (8.3) | 4 (57.1) | 0.1 |
| FEV1, % predicted (±SEM) | 84.4 (±3.1) | 84.3 (±4.9) | 79.5 (±11.8) | 88.8 (±5.0) | 80.0 (±8.6) | 0.8 |
| NPF, L/min (IQR) | 95 (55–130) | 100 (80–135) | 140 (80–160) | 100 (50–125) | 60 (50–90) | 0.4 |
| Lund-Mackay score (IQR) | 19 (14–21) | 20 (17–21) | 13 (12–14) | 16 (14–20) | 22 (21–24) | 0.02 |
|
Peripheral blood eosinophil count k/µL (±SEM) |
0.7 (±0.07) | 0.6 (±0.08) | 0.6 (±0.09) | 0.7 (±0.14) | 1.0 (±0.2) | 0.2 |
| ACT score (±SEM) | 18 (±0.7) | 19 (±1.0) | 16 (±1.7) | 18 (±1.2) | 19 (±2.2) | 0.5 |
| RQLQ score (IQR) | 2.5 (1.8–4.2) | 2.9 (1.5–4.2) | 2.8 (1.5–4.5) | 2.4 (1.9–3.7) | 3.5 (2.3–4.2) | 0.9 |
| 15-HETE, pg/mL plasma (IQR) | 5850 (4825–7000) | 7006 (6056–8688) | 5969 (5081–7381) | 4800 (4238–5575) | 5663 (5325–6363) | 0.0005** |
ESS – endoscopic sinus surgery
ICS – inhaled corticosteroids
FEV1 – forced expiratory value in 1 second
NPF – nasal peak flow
ACT score – asthma control test, higher value corresponds to better asthma control
RQLQ score – rhinoconjunctivitis quality of life questionnaire, lower value corresponds to better ocular-nasal symptom control
15-HETE – 15-hydroxyeicosatetraenoic acid
*
Treatment outcomes were evaluated using the change from baseline in ACT and RQLQ scores
**
p-value for comparison between patients with improvement of symptoms vs. with worsening of symptoms
Values are expressed as means (± standard error of the means, SEM) or medians (interquartile range, IQR)